成人急性髓系白血病的生物学特点及治疗进展  

Biological Characteristics and Treatment Progress of Adult Acute Myeloid Leukemia

作　　者：路肖肖 赵芳[1] 

机构地区：[1]河北医科大学沧州市中心医院,河北 沧州

出　　处：《临床医学进展》2024年第3期2076-2089,共14页Advances in Clinical Medicine

摘　　要：急性髓系白血病(Acute Myeloid Leukemia, AML)是一类起源于造血干细胞的克隆性血液系统恶性肿瘤。目前AML患者的诊断分型、治疗选择及预后评估已经进入了分子生物学时代,随着二代测序等新的分子生物学技术的发展和应用,我们对AML患者有了更全面和更深入的了解。AML患者具有高度异质性,预后差,对不能耐受强化疗以及复发难治的AML患者来说,靶向治疗、免疫治疗等新的治疗选择的出现为这部分患者带来了希望。本文将对成人AML患者的生物学特点及治疗进展进行综述。Acute Myeloid Leukemia (AML) is a type of clonal hematological malignancies originating from hematopoietic stem cells. At present, the diagnosis and classification, treatment selection and prognosis assessment of AML patients have entered the era of molecular biology. With the development and application of new molecular biology technologies such as second-generation sequencing, we have a more comprehensive and in-depth understanding of AML patients. AML patients are highly heterogeneous and have a poor prognosis. For AML patients who cannot tolerate strong chemotherapy or relapse and are difficult to treat, the emergence of new treatment options such as targeted therapy and immunotherapy has brought hope to these patients. This article reviews the biological characteristics and treatment progress of adult AML patients.

关 键 词：急性髓系白血病 生物学特点 治疗进展 靶向治疗 预后评估 

分 类 号：R73[医药卫生—肿瘤]